IMPLICATIONS OF CXCR3 EXPRESSION ON MYELOID CELLS FOR IMMUNOTHERAPY OF CANCER AND MYELOID-MEDIATED DISEASES
European Patent
23821436.5
Filed on 2025-06-06
23821436.5
Filed on 2025-06-06
IMPLICATIONS OF CXCR3 EXPRESSION ON MYELOID CELLS FOR IMMUNOTHERAPY OF CANCER AND MYELOID-MEDIATED DISEASES
US Application 19/126,866
Filed on 2025-05-02
Filed on 2025-05-02
NOVEL CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY
China
202510520314.2
Filed on 2025-04-24
202510520314.2
Filed on 2025-04-24
METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION
The Netherlands
18782605.2
Filed on 2018-09-17
18782605.2
Filed on 2018-09-17
METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION
Switzerland
18782605.2
Filed on 2018-09-17
18782605.2
Filed on 2018-09-17
METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION
Ireland
18782605.2
Filed on 2018-09-17
18782605.2
Filed on 2018-09-17
METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION
United Kingdom
18782605.2
Filed on 2018-09-17
18782605.2
Filed on 2018-09-17
METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION
Belgium
18782605.2
Filed on 2018-09-17
18782605.2
Filed on 2018-09-17
METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION
Germany
18782605.2
Filed on 2018-09-17
18782605.2
Filed on 2018-09-17